Related Experiment Videos
Insights
Newborn screening for cystic fibrosis (CF) is now feasible. Early diagnosis and treatment are likely to improve outcomes, despite current evidence limitations, and raise ethical considerations for prenatal testing and carrier screening.
Area of Science:
- Medical screening
- Genetics
- Public health
Background:
- Cystic fibrosis (CF) is a genetic disorder with significant patient and family burden.
- Advances in screening technologies enable widespread newborn testing for CF.
Purpose of the Study:
- To evaluate the feasibility and implications of population-wide newborn screening for cystic fibrosis.
- To discuss the ethical considerations surrounding neonatal diagnosis, early treatment, and prenatal/carrier testing.
Main Methods:
- Review of current screening methodologies for cystic fibrosis in neonates.
- Analysis of existing evidence on the benefits of early diagnosis and treatment.
- Discussion of ethical issues related to genetic testing for cystic fibrosis.
Main Results:
- Practicable methods for whole population screening of neonates for cystic fibrosis are available.
- Evidence suggests, though not unequivocally proven, that early diagnosis and treatment likely improve prognosis.
- Ethical challenges arise with developing prenatal diagnostic tests and carrier detection methods.
Conclusions:
- Neonatal screening for cystic fibrosis is technically feasible and ethically supported by potential benefits of early intervention.
- The development of prenatal and carrier testing presents complex ethical dilemmas for heterozygotes and healthcare providers.
- Policy decisions regarding neonatal screening must consider the substantial financial and emotional impact of cystic fibrosis on affected families.
Abstract:
Practicable methods are now available for whole population screening of neonates for cystic fibrosis. Although diagnosis and treatment of the disease from birth has not yet been unequivocally shown to improve prognosis, existing evidence suggests that this is likely. Further ethical reasons are proposed in support of neonatal diagnosis and early treatment. The development of tests for prenatal diagnosis and carrier detection is under active investigation, and raises ethical problems for heterozygotes and their medical advisers. The heavy financial and emotional burden this disease imposes on the patient and the family should not be underestimated when policy decisions are made.